What is FUJIFILM Cellular Dynamics?
FUJIFILM Cellular Dynamics is a leading provider of human induced pluripotent stem cell (iPSC) services and products. The company offers a comprehensive portfolio of cell types, including cardiac, neural, and immune cells, which are critical for advancing research in disease modeling, drug discovery, and toxicology. By supplying researchers and organizations within the life sciences sector, FUJIFILM Cellular Dynamics plays a crucial role in accelerating therapeutic development and cell therapy applications. Furthermore, the company extends its expertise through contract development and manufacturing organization (CDMO) services, producing clinical-grade human cells to meet stringent regulatory standards. Their commitment to innovation positions them at the forefront of scientific advancement in regenerative medicine.
How much funding has FUJIFILM Cellular Dynamics raised?
FUJIFILM Cellular Dynamics has raised a total of $161.8M across 6 funding rounds:
Private Equity
$18M
Series B
$40.6M
Private Equity
$21M
Multiple Rounds
$82.2M
Private Equity (2008): $18M, investors not publicly disclosed
Series B (2010): $40.6M, investors not publicly disclosed
Private Equity (2012): $21M, investors not publicly disclosed
Grant (2013): $16M featuring California Institute of Regenerative Medicine
Debt (2013): $20M, investors not publicly disclosed
Stock Issuance/Offering (2013): $46.2M, investors not publicly disclosed
Key Investors in FUJIFILM Cellular Dynamics
California Institute of Regenerative Medicine
The California Institute of Regenerative Medicine (CIRM) is a state agency that funds stem cell research. Their involvement suggests a focus on advancing regenerative medicine and therapeutic applications of stem cell technology.
What's next for FUJIFILM Cellular Dynamics?
With the recent major strategic investment, FUJIFILM Cellular Dynamics is poised for significant expansion and technological advancement. The capital infusion is anticipated to bolster its research and development capabilities, potentially leading to the creation of novel iPSC-derived cell therapies and enhanced drug discovery platforms. The company's focus on providing high-quality, clinical-grade cells suggests a strategic push towards commercialization and broader market penetration. Future endeavors may include strategic partnerships to further leverage their iPSC technology for a wider range of therapeutic areas and to scale up manufacturing processes to meet increasing global demand for advanced cell-based solutions.
See full FUJIFILM Cellular Dynamics company page
